Currently, fewer than one in five large employers are covering such prescriptions despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, according to a KFF analysis earlier ...
Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...